ESR1 and breast carcinoma: A meta-analysis performing an adjusted indirect comparison among the three CDK 4/6i efficacy and toxicity revealed they are equally effective in either first- or second-line therapy for estrogen receptor-positive advanced breast cancer (Petrelli et al., 2019).